Hyperfine, Inc.HYPR

NasdaqHealthcareElectromedical & Electrotherapeutic Apparatus
Price (close)
$0.80
Market cap
$79.4M
P/E
—
Revenue (TTM)
$16.5M
Net income
-$34.9M
Dividend yield
—
1-year total return
-45.5%
Net margin
-210.8%
Revenue growth
53.2%
Debt / equity
0.36x

What Hyperfine, Inc. does.

We are an innovative health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (“AI”)-powered portable ultra-low-field (“ULF”) magnetic resonance (“MR”) brain imaging. Our Swoop® Portable MR Imaging® System (“Swoop® system”) produces high-quality images at a significantly lower magnetic field strength than conventional magnetic resonance imaging (“MRI”) scanners. Our Swoop® system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated patient-friendly experience, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop® system is a portable, ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. Healthcare professionals can use the Swoop® system to make effective clinical diagnoses and decisions in various care settings where conventional MRI devices are inaccessible and/or when they are not readily available. The portable design of our Swoop® system make it safely and readily accessible anywhere in a hospital, clinic, physician’s office, or patient care site and it does not require any special facilities accommodations. The easy to use, iPad-based interface makes its operation easy to learn and it does not require specialized personnel to operate safely. ULF MR does not expose patients to harmful ionizing radiation and compares favorably in this regard to X-ray computed tomography (“CT”) or positron emission tomography (“PET”).

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$294,000$1.5M$6.8M$11.0M$12.9M$13.6M
Net income-$23.4M-$64.9M-$44.2M-$44.2M-$40.7M-$35.6M
Free cash flow-$23.1M-$49.9M-$72.9M-$42.6M-$39.1M-$29.1M

More on HYPR.

Figures from Hyperfine, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.